The Filing Desk

Immunocore vs Tarsus Pharmaceuticals

Immunocore IMCR · Tarsus Pharmaceuticals TARS · Biotechnology

Tarsus Pharmaceuticals reported revenue of $451 million in fiscal 2025, about the same as Immunocore's $400 million in fiscal 2025. Immunocore's revenue grew 28.9% in its latest year, and Tarsus Pharmaceuticals' grew 146.7%. Immunocore had an operating margin of -11.3%, against -15.7% at Tarsus Pharmaceuticals. Free cash flow was −$15 million at Immunocore and −$22 million at Tarsus Pharmaceuticals.

Side by side

ImmunocoreTarsus Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$400M$451M
Revenue growth28.9%146.7%
Revenue growth a year, last 5 years——
Gross margin98.7%—
Operating margin−11.3%−15.7%
Net margin−8.9%−14.7%
Free cash flow−$15M−$22M
Free cash flow margin−3.8%−4.9%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count0.7%11.1%
Last close$26.63$77.67
P/E at the last close——
Insider trades, last 12 monthssold $5.6 millionsold $20.8 million
Piotroski F-score—4 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ImmunocoreTarsus Pharmaceuticals
Operating margin
Percent of revenue
ImmunocoreTarsus Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ImmunocoreTarsus Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Immunocore and Tarsus Pharmaceuticals pages.